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Most of the information on predisposing factors and mortality in status epilepticus (SE) arises from data obtained from patients
presenting to the casualty department. However, another population which is frequently seen by consultative neurologists are
medically ill patients who develop SE while in hospital. These patients are often notoriously difficult to treat once SE arises.
We sought to characterize patients at risk for SE arising when they are hospitalized for other reasons. By doing this, risk factors
for developing SE and prognostic indicators might be determined.
We retrospectively reviewed records from three urban hospitals in the United States to identify hospitalized patients devel-
oping SE over a 1 year period. SE was defined as a clinical seizure lasting 30 minutes or longer, or repeated seizures without
recovery. Patients who were admitted in SE or for an epilepsy-related problem, or who were less than 1 year old were excluded
from the study.
Forty-one patients with in-hospital SE were identified. There were 28 males and 13 females with an age range from 1 to
91 years (mean: 60 years, median: 65 years). The mean interval from hospital admission to the onset of status epilepticus
was 26 days. Nineteen (46%) patients had a prior history of either epilepsy or symptomatic seizures, and of these, 10 were
inadequately treated as judged by serum anticonvulsant levels at the time SE developed. Focal brain abnormality was present
in 26 (63%) patients, the most common of which was stroke (17 patients). Major metabolic derangements including hypoxia,
electrolyte imbalance, hepatic encephalopathy, and sepsis were present in 23 (56%) patients. Eleven (27%) patients were being
treated with theophylline preparations at the time SE developed. Mortality in this group of patients with in-hospital SE was
61% (25 deaths), with about one-third dying while in status, and two-thirds dying subsequently in hospital. In this retrospective
study, there was no clear relationship between mortality and the duration of SE in this group of patients.
In-hospital development of SE is usually related to underlying focal brain abnormality, especially stroke, in combination
with systemic metabolic derangement. Prognosis is poor, and appears to be more related to underlying conditions rather than to
status duration. More accurate prospective studies are warranted.
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INTRODUCTION
Most data on status epilepticus (SE) derive from stud-
ies of patients admitted to the hospital in SE or with
SE treated in the field. The majority of these cases
of SE in adults occur in patients with a known his-
tory of epilepsy1–5, in patients with known structural
lesions of the central nervous system, usually due to
cerebrovascular disease4, or in patients with alcohol
abuse6, 7. In children, infection is the most common
underlying precipitating factor4. With modern man-
agement prognosis for patients has improved. Mor-
tality in adults approximates 10–30%8, 9, although the
mortality is higher in the elderly4, and in patients with
subtle SE10. Status epilepticus developing in patients
already hospitalized for reasons unrelated to epilepsy
or prior seizures is most likely due to symptomatic
SE, secondary to a variety of medical causes11. How-
ever, no study has specifically addressed SE develop-
ing in patients already in the hospital who had not ini-
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tially been admitted because of epilepsy or seizure ex-
acerbation. This may represent a distinct subgroup of
patients, with unique risk factors and a higher mortal-
ity. Our study thus sought to characterize patients who
developed in-hospital SE. We describe associated ae-
tiological factors and outcome associated with SE in
41 patients who were initially admitted to the hospital
for reasons other than seizures, in whom SE developed
while in hospital.
MATERIALS AND METHODS
A retrospective analysis was performed in three ur-
ban hospitals in the United States, and the charts of all
patients who developed clinical SE over a 1 year pe-
riod were reviewed. Charts were obtained from medi-
cal records following a search under a primary or sec-
ondary discharge diagnoses of epilepsy, seizures, SE,
and convulsive disorders. Also, we reviewed the EEG
and Neurology service consult log books, searching
for patients with diagnoses suggesting SE. SE was de-
fined as a seizure lasting greater than 30 minutes or
repeated seizures without recovery of normal neuro-
logical function between attacks. Information was ob-
tained about concurrent medical conditions, medica-
tions, duration, outcome, and EEG findings. Patients
were excluded if they (a) arrived at the casualty depart-
ment in SE, (b) were admitted for an epilepsy-related
problem such as video monitoring or drug intoxica-
tion, or (c) were less than 1 year old.
RESULTS
Patient characteristics
Forty-one patients with SE were identified and in-
cluded for study. There were 28 males and 13 females.
The age range was between 1 and 91 years with a mean
of 60 years and a median of 65 years. Four patients
were aged between 1 and 20 years, 22 were aged be-
tween 21 and 70 years, and 15 were aged 71 years
or older. The mean interval between hospital admis-
sion and the development of SE was 26 days. Eight
patients (20%) had a history of pre-existing epilepsy
before hospital admission. Eleven other patients (27%)
had developed an acute symptomatic, sporadic single
seizure while in-hospital before the development of
SE. Thus a total of 19 patients (47%) had a history of
seizures before they developed SE. Of these, six were
not on any anticonvulsant medication at the time SE
developed, and four had ‘sub-therapeutic’ serum drug
concentrations. Therefore 10 of the 19 patients with a
prior history of seizures may have been undertreated at
the onset of SE. In most cases, the presence of convul-
sive vs. non-convulsive SE could not be determined.
Table 1: Pre-existing conditions. Many patients had more
than one underlying condition.
Disorder n %
Electrolyte imbalance 12 29
Renal disease 8 20
Hepatic disease 7 17
Pulmonary disease 18 44
Cardiac disease 15 37
Theophylline treatment 11 27
Cardiac surgery 2 5
Hypertensive encephalopathy 2 5
Hypoxic-ischemic encephalopathy 6 15
Cerebrovascular disease
Recent 9 22
Remote 8 20
Brain surgery/tumor 8 20
Sepsis 5 12
Underlying conditions (Table 1)
Eighteen patients (44%) had active pulmonary disease,
15 (37%) had active cardiac disease, eight (20%) had
renal impairment and seven (17%) had hepatic impair-
ment. Twenty-nine patients (71%) had multiple medi-
cal problems. A significant metabolic contribution was
present in 23 patients (56%). This included hypoxia,
sepsis, hepatic encephalopathy, electrolyte imbalance,
and organ failure. Diabetes mellitus was present in six
patients (15%). Eleven patients (27%) who developed
SE while in hospital were taking a theophylline prepa-
ration, although only one had a serum theophylline
concentration in the ‘toxic’ range. Two patients devel-
oped SE following cardiac surgery, and another two
patients had underlying hypertensive encephalopathy.
Focal presentation of SE
Significant focal CNS disturbance was present in
25 patients (61%). Of these, 17 had evidence of cere-
brovascular disease (equally divided between recent
and remote events), six had recent neurosurgery, and
five had a primary or metastatic brain tumour. Many
patients had an apparent focal presentation to their SE.
When EEG was performed during SE, focal abnormal-
ities were common. However, this was not predictive
of a prior or subsequent finding of a focal CNS pro-
cess. Focal abnormalities on neurological examination
or focal EEG abnormalities were found in 18 of 25
of patients (72%) with prior or subsequent focal CNS
disease, and in 11 of 16 (69%) without focal CNS dis-
ease.
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Outcome and mortality
Overall, 25 of the 41 patients died (mortality of 61%).
Of these, nine patients died while in SE, and 16 died
subsequently in hospital. Five patients were left in a
vegetative state or were left totally disabled and de-
pendent. Only eight patients (20%) returned to base-
line and left the hospital.
Outcome and duration of status epilepticus
There was little relationship between the duration of
SE and mortality in this study population. Of those
who were in SE for 2 hours or less (15 patients), the
mortality was 57%, in comparison with a mortality of
60% in those (26 patients) who were in SE for longer
than 2 hours.
DISCUSSION
Our study describes a group of hospitalized patients
who developed SE following admission for a non-
epilepsy-related problem. Our findings suggest that
the development of in-hospital SE carries a poor prog-
nosis. This appears to be related more to the underly-
ing condition rather than the duration of SE. Many of
these patients with in-hospital SE also had evidence of
a focal CNS lesion. Many patients had multiple med-
ical and systemic metabolic derangements in addition
to focal structural brain disease. The exact immediate
cause triggering SE was often unclear and was likely
to be multifactorial in some patients.
Focal CNS disturbance is often present in hospi-
talized SE patients, especially cerebrovascular dis-
ease. Interestingly, focal abnormalities detected dur-
ing SE on neurological or EEG examination are as
likely to occur in patients without known structural
brain disease as in those with documented struc-
tural disease. Therefore, such findings should be inter-
preted clinically with caution. Transient metabolic and
other homeostatic disturbance (e.g. hypoglycemia)
can cause focal neurological symptoms and signs12,
perhaps on the basis of occult cerebrovascular disease.
Both recent and remote stroke were associated with
SE, and this is in agreement with a large prospective
study of SE in which cerebrovascular disease was par-
ticularly prevalent in elderly patients4, accounting for
61% of all cases of SE in this age group.
Cerebrovascular disease is also a common precipi-
tant of isolated seizures in the elderly general hospi-
tal population13. However, in medical and surgical in-
tensive care, narcotic drug withdrawal and metabolic
abnormalities are the most common predisposing fac-
tors for the development of new-onset seizures14.
Not surprisingly, metabolic derangement, including
organ failure and electrolyte imbalance, and hypoxia-
ischaemia were also important predisposing factors in
our study, being estimated to have a causal relationship
to SE in about 56% of patients.
An interesting finding in our study was the associa-
tion between theophylline use and SE in about a quar-
ter of patients. The rate of theophylline use in similar
sick patients who did not develop SE is not known, but
would be expected to be less than 25%. Both acute and
chronic theophylline toxicity are well known to pre-
dispose to seizures, and seizures associated with ther-
apeutic levels have also been reported15. In chronic
theophylline toxicity, serum levels do not appear to
be predictive of seizure risk16. It is possible that even
theophylline levels in the therapeutic range may pre-
dispose to seizures in sick hospitalized patients with
multiple metabolic abnormalities and organ failure. In
this group of patients theophylline may need to be used
with caution and other bronchodilator therapy consid-
ered instead when possible. The mechanism by which
theophylline lowers the seizure threshold is unclear,
but may be due to antagonism of adenosine17.
A prior history of epilepsy was less common in our
study than in other studies of SE, again emphasizing
the importance of the onset of acute illness as a cause
of SE in hospitalized patients. Among our 19 patients
with a history of prior seizures, up to 10 may have been
undertreated at the time SE developed. In patients with
organ failure, free levels of anticonvulsant medication
should be monitored when possible.
In our study, the high mortality was probably related
to the aetiology of underlying medical illness. It is pos-
sible that mortality is not just a direct effect of the un-
derlying medical disorders present in these patients,
but that, in addition, the development of symptomatic
SE in these sick patients contributes further to their
poor prognosis. This has also previously been sug-
gested for patients with cerebrovascular disease who
develop SE4. SE has important adverse effects includ-
ing increased metabolic demand, hyperpyrexia, and
cerebral hypoxia18, all of which may overwhelm al-
ready impaired homeostatic mechanisms in compro-
mised sick patients in hospital. The high mortality in
our study agrees with a small previous analysis of
in-hospital SE in a subgroup of more heterogeneous
patients who developed SE2. In addition, these find-
ings are consistent with the results of a recent large
randomized trial of four different standard treatments
for convulsive SE in which the 30 day mortality for
patients with clinically obvious SE was 27% compared
with 65% for those with subtle SE10. Patients in the
latter group had much higher rates of concomitant se-
rious general medical illnesses10, and thus are more
like the in-hospital patients of our study.
Prognosis did not appear dependent on the duration
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of SE in our patients, in contrast to the findings of
other studies2, 3, 19. However, our retrospective study is
limited in drawing firm conclusions about the relation-
ship of SE duration and prognosis, even in this specific
population of patients. It is possible that some patients
in our series may have gone unrecognized for some
hours before diagnosis of SE was made and treatment
initiated. On the other hand, the underlying diseases
may have been so critical to outcome, that SE duration
had little additional impact.
In conclusion, the development of in-hospital SE ap-
pears to be associated with a high incidence of fo-
cal brain disease and metabolic abnormalities. Theo-
phylline therapy may predispose to the development
of SE in hospitalized patients with multiple medical
problems. Hospitalized patients with serious comor-
bid illnesses or central focal lesions with a history of
prior seizures may need to be treated with therapeu-
tic anticonvulsant medication. In-hospital SE carries a
poor prognosis, probably related to underlying medi-
cal problems. These findings indicate that, compared
to an outpatient population with SE, this may be a
difficult group to treat. Due to the limited retrospec-
tive nature of our study, all risk factors could not be
adequately assessed. New treatments are needed for
patients with SE, especially for those with underly-
ing serious concomitant illness10, and new efforts to
better prospectively define risk factors and treatment
strategies in this population would be useful. Also,
since this population’s prognosis may differ, prospec-
tive treatment protocols may need to stratify patients
on this variable, in addition to other previously recog-
nized variables such as seizure duration, which do not
seem as critical in this population.
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